Unveiling the shield: Troglitazone's impact on epilepsy‐induced nerve injury through ferroptosis inhibition

• Published in: CNS neuroscience & therapeutics 2024-08, Vol.30 (8), p.e14911-n/a
• Main Authors: Wang, Zhi‐Bin, Liu, Jun‐Yan, Jiang, Shi‐Long, Zhuo, Wei, Xie, Pan, Dai, Wen‐Ting, Mao, Xiao‐Yuan, Liu, Zhao‐Qian
• Format: Article
• Language: English
• Subjects: Animals; Anticonvulsants - pharmacology; Anticonvulsants - therapeutic use; brain damage; Brain injury; Brain research; Cell death; Central nervous system; Cholecystokinin; Convulsions & seizures; Down-regulation; Drug dosages; Drug resistance; Epilepsy; Epilepsy - chemically induced; Epilepsy - drug therapy; Ferroptosis; Ferroptosis - drug effects; Ferroptosis - physiology; Flow cytometry; Gene expression; Glutamic Acid - metabolism; Hippocampus; Hippocampus - drug effects; Hippocampus - metabolism; Hippocampus - pathology; Kainic acid; Kainic Acid - toxicity; Laboratory animals; Lipids; Male; Membrane potential; Membrane Potential, Mitochondrial - drug effects; Mice; Mice, Inbred C57BL; Mitochondria; Morphology; Neurons - drug effects; Neurons - metabolism; Neuroprotection; Neuroprotective Agents - pharmacology; Original; Plaur; Risk factors; Scanning electron microscopy; Seizures; Toxicity; Troglitazone
• ISSN: 1755-5930; 1755-5949; 1755-5949
• DOI: 10.1111/cns.14911

Background Epilepsy is a widespread central nervous system disorder with an estimated 50 million people affected globally. It is characterized by a bimodal incidence peak among infants and the elderly and is influenced by a variety of risk factors, including a significant genetic component. Despite the use of anti‐epileptic drugs (AEDs), drug‐refractory epilepsy develops in about one‐third of patients, highlighting the need for alternative therapeutic approaches. Aims The primary aim of this study was to evaluate the neuroprotective effects of troglitazone (TGZ) in epilepsy and to explore the potential mechanisms underlying its action. Methods We employed both in vitro and in vivo models to assess TGZ's effects. The in vitro model involved glutamate‐induced toxicity in HT22 mouse hippocampal neurons, while the in vivo model used kainic acid (KA) to induce epilepsy in mice. A range of methods, including Hoechst/PI staining, CCK‐8 assay, flow cytometry, RT‐PCR analysis, Nissl staining, scanning electron microscopy, and RNA sequencing, were utilized to assess various parameters such as cellular damage, viability, lipid‐ROS levels, mitochondrial membrane potential, mRNA expression, seizure grade, and mitochondrial morphology. Results Our results indicate that TGZ, at doses of 5 or 20 mg/kg/day, significantly reduces KA‐induced seizures and neuronal damage in mice by inhibiting the process of ferroptosis. Furthermore, TGZ was found to prevent changes in mitochondrial morphology. In the glutamate‐induced HT22 cell damage model, 2.5 μM TGZ effectively suppressed neuronal ferroptosis, as shown by a reduction in lipid‐ROS accumulation, a decrease in mitochondrial membrane potential, and an increase in PTGS2 expression. The anti‐ferroptotic effect of TGZ was confirmed in an erastin‐induced HT22 cell damage model as well. Additionally, TGZ reversed the upregulation of Plaur expression in HT22 cells treated with glutamate or erastin. The downregulation of Plaur expression was found to alleviate seizures and reduce neuronal damage in the mouse hippocampus. Conclusion This study demonstrates that troglitazone has significant therapeutic potential in the treatment of epilepsy by reducing epileptic seizures and the associated brain damage through the inhibition of neuronal ferroptosis. The downregulation of Plaur expression plays a crucial role in TGZ's anti‐ferroptotic effect, offering a promising avenue for the development of new epilepsy treatments. Troglitazone can pr